The survival and prognostic factors of primary testicular lymphoma: two-decade single-center experience.

Run-zhuo MA; Lei Tian; Li-yuan Tao; Hui-ying HE; Min LI; Min LU; Lu-lin MA; Hui Jiang; Jian LU

Return

The survival and prognostic factors of primary testicular lymphoma: two-decade single-center experience.

Author: Run-Zhuo MA ¹ ; Lei TIAN ² ; Li-Yuan TAO ³ ; Hui-Ying HE ⁴ ; Min LI ⁴ ; Min LU ⁴ ; Lu-Lin MA ¹ ; Hui JIANG ¹ ; Jian LU ¹
Author Information

1. Department of Urology, Peking University Third Hospital, Beijing 100191, China.
2. Department of Hematology, Peking University Third Hospital, Beijing 100191, China.
3. Department of Biostatistics, Peking University Third Hospital, Beijing 100191, China.
4. Department of Pathology, Peking University Third Hospital, Beijing 100191, China.
Publication Type:Journal Article
Keywords: local treatment modalities; prognostic factors; prophylaxis contralateral orchiectomy; prophylaxis contralateral radiotherapy; testicular lymphoma
MeSH: Aged; Aged, 80 and over; Antineoplastic Agents/therapeutic use*; Asian People; China/epidemiology*; Humans; Kaplan-Meier Estimate; Lymphoma/mortality*; Male; Middle Aged; Prognosis; Progression-Free Survival; Retrospective Studies; Rituximab/therapeutic use*; Survival Analysis; Testicular Neoplasms/mortality*; Treatment Outcome
From: Asian Journal of Andrology 2018;20(6):615-620
CountryChina
Language:English
Abstract: This study aims to investigate the effect of different local testicular treatments and validate common prognostic factors on primary testicular lymphoma (PTL) patients. We retrospectively reviewed the clinical records of 32 patients from 1993 to 2017 diagnosed with PTL and included 22 patients for analysis. The Kaplan-Meier method, Log-rank test, and multivariate Cox proportional hazard regression analysis were applied to evaluate progression-free survival (PFS), overall survival (OS), and determine prognosis predictors. The median follow-up time was 30 months. Median OS and PFS were 96 months and 49 months, respectively. In univariate analysis, advanced Ann Arbor stage (III/IV) (P < 0.001), B symptoms (P < 0.001), and extranodal involvement other than testis (P = 0.001) were significantly associated with shorter OS and PFS. In multivariate analysis, Ann Arbor stage was significantly associated with OS (OR = 11.58, P = 0.049), whereas B symptom was significantly associated with PFS (OR = 11.79, P= 0.049). In the 10 patients with the systemic usage of rituximab, bilateral intervention could improve median OS from 16 to 96 months (P = 0.032). The study provides preliminary evidence on bilateral intervention in testes in the rituximab era and validates common prognostic factors for Chinese PTL patients.